marketed under the brand names Estracyt and Emcyt, but has also been sold under a number of other brand names, including Amsupros, Biasetyl, Cellmustin, Estramustin HEXAL, Estramustina Filaxis, Estranovag, Multosin, Multosin Injekt, Proesta, Prostamustin, and Suloprost. Availability EMP is marketed in the United States, Canada, and Mexico under the brand name Emcyt, whereas the medication is marketed under the brand name Estracyt in the United Kingdom and elsewhere throughout Europe as well as in Argentina, Chile, and Hong Kong. It has been discontinued in a number of countries, including Australia, Brazil, Ireland, and Norway. Research EMP has been studied in the treatment of other cancers such as glioma and breast cancer. It has been found to slightly improve quality of life in people with glioma during the first 3 months of therapy. References Further reading Antiandrogens Antigonadotropins Carbamates Chloroethyl compounds DNA replication inhibitors Estradiol esters Estranes Estrogens Hormonal antineoplastic drugs Mitotic inhibitors Nitrogen mustards Organochlorides Phosphate esters Pfizer brands Prodrugs Prostate cancer